// App-Quantinova.ai

: Triamcinolone acetonide extended-release injectable suspension (TA-ER) provides clinically relevant improvements in pain and function of knee osteoarthritis: a pooled analysis of 3 randomized clinical trials employing composite assessments

Researchers

Presenter

  • N.P. Katz

Principal Investigators

  • P.G. Conaghan

  • V.B. Kraus

  • J. Lufkin

  • J.R. Johnson

  • S. Kelley

Medical Centers

  • Analgesic Solutions, Tufts Univ. Sch. of Med., Natick, Boston, MA, USA

  • Leeds Inst. of Rheumatic and Musculoskeletal Med., Univ. of Leeds & NIHR Leeds BioMed. Res. Ctr., Leeds, United Kingdom

  • Duke Univ. Sch. of Med., Durham, NC, USA

  • Flexion Therapeutics, Inc., Burlington, MA, USA,

  • Summit Analytical, Denver, CO, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Genetic Disorder

Disease

  • Knee osteoarthritis

  • Spondylocostal dysostosis 5

Biomarkers

  • N/A

Drug/Treatment

  • Triamcinolone acetonide

  • ReadySharp-P80

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Prospective

  • Parallel Group

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved